In contrast, detection of less than 101 HER2+EVs per μl of plasma and/or HER2 fluorescence intensity ≤ 1.5 × 103 characterised breast cancer patients with a low probability of having an HER2pos tumor. This evidence concerns the gene ERBB2 and breast cancer.